Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...
Approved in 2018, mogamulizumab is a second-line treatment for cutaneous T-cell lymphoma (Sézary syndrome) and mycosis fungoides. Side effects often manifest as drug rashes, lymphocytopenia ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne ...